Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings

Abstract Introduction Cutaneous lupus erythematosus (CLE), particularly discoid lupus erythematosus (DLE), is a chronic autoimmune condition driven in part by type I interferon signaling. No systemic therapies are specifically approved for CLE, and management is often extrapolated from systemic lupu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Francesco D’Oria, Francesco Piscazzi, Paola Facheris, Giulio Foggi, Marco Ardigò, Antonio Costanzo, Mario Valenti
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2026-04-01
Col·lecció:	Dermatology and Therapy
Matèries:	Discoid lupus erythematosus Cutaneous lupus erythematosus Deucravacitinib TYK2 inhibition Plaque psoriasis
Accés en línia:	https://doi.org/10.1007/s13555-026-01742-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!